Researcher
Jo Van Ginderachter
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Applied immunology
Affiliations
- Cellular and Molecular Immunology (Research group)
Responsible
From1 Oct 1995 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 31 Dec 2023 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Van Ginderachter Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2012 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2010 → 20 Oct 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 10 of 26
- Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapyFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Blocking the immunoregulatory family members D-dopachrome tautomerase (D-DT) and Macrophage Migration Inhibitory Factor (MIF) to improve immunotherapy of cancerFrom1 Nov 2022 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- SBO Project : LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Optimized anti-Neuropilin-1 Nanobody formats as cancer therapyFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immunological memory of the macrophage niche (MacNicheMemo).From1 Jan 2021 → TodayFunding: BOF - iBOF
- Blocking Lipocalin-2 (Lcn-2) using Nanobodies as novel cancer therapyFrom1 Nov 2020 → TodayFunding: FWO fellowships
- Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization systemFrom1 May 2020 → TodayFunding: Hercules - Small and Medium size research infrastructure
Publications
21 - 30 of 101
- Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation(2021)
Authors: Federico Virga, Federica Cappellesso, Benoit Stijlemans, Anne-Theres Henze, Rosa Trotta, Jonas Van Audenaerde, Ananda S Mirchandani, Manuel A Sanchez-Garcia, Jolien Vandewalle, Francesca Orso, et al.
- Myeloid tumor necrosis factor and heme oxygenase-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion(2021)
Authors: Desislava Germanova, Jiri Keirsse, Arnaud Köhler, Jean-François Hastir, Peter Demetter, Sandrine Delbauve, Yvon Elkrim, Laurine Verset, Lionel Larbanoix, Nicolas Preyat, et al.
Pages: 1276-1288 - IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D(2021)
Authors: Máté Kiss, Lieselotte Vande Walle, Pedro H V Saavedra, Els Lebegge, Helena Van Damme, Aleksandar Murgaski, Junbin Qian, Manuel Ehling, Samantha Pretto, Evangelia Bolli, et al.
Pages: 309-323 - Development and Characterization of Nanobodies Targeting the Kupffer Cell(2021)
Authors: Fang Zheng, Jinhong Zhou, Zhenlin Ouyang, Jiaxin Zhang, Xinyi Wang, Serge Muyldermans, Jo A Van Ginderachter, Nick Devoogdt, Yurong Wen, Steve Schoonooghe, et al.
- Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment(2021)
Authors: José M Carbó, Theresa E León, Joan Font-Díaz, Juan Vladimir De la Rosa, Antonio Castrillo, Felix R Picard, Daniel Staudenraus, Magdalena Huber, Lídia Cedó, Joan Carles Escolà-Gil, et al.
Pages: 968-985 - Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy(2021)
Authors: Helena Van Damme, Bruno Dombrecht, Máté Kiss, Heleen Roose, Elizabeth Allen, Eva Van Overmeire, Daliya Kancheva, Liesbet Martens, Aleksandar Murgaski, Pauline Bardet, et al.
- Kanker-geïnduceerde lokale en systemische herprogrammering van myeloïde cellen en de impact ervan op ziekteprogressie(2021)
Authors: Máté Kiss, Jo A Van Ginderachter
- Multi-omic analysis of glioblastoma-associated myeloid cells across species and disease stages(2021)
Authors: Ana Rita Pombo Antunes, Jo A Van Ginderachter
- Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy(2020)
Authors: Els Lebegge, Sana M Arnouk, Pauline Bardet, Máté Kiss, Geert Raes, Jo A Van Ginderachter
Pages: 1-14 - A Critical Blimp-1-Dependent IL-10 Regulatory Pathway in T Cells Protects From a Lethal Pro-inflammatory Cytokine Storm During Acute Experimental Trypanosoma brucei Infection.(2020)
Authors: Carl De Trez, Benoit Stijlemans, Viki Bockstal, Jennifer Cnops, Hannelie Korf, Jacques Van Snick, Guy Caljon, Eric Muraille, Ian R Humphreys, Louis Boon, et al.
Pages: 1085
Patents
1 - 6 of 6
- Tumor-associated dendritic cell preparations and uses thereof (Inventor)
- Non-blocking human ccr8 binders (Inventor)
- Human ccr8 binders (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer (Inventor)
- Murine cross-reactive human ccr8 binders (Inventor)